Current issues in kidney cancer

Current issues highlight some of the latest research into kidney cancer, new therapies becoming available and new drug treatments coming to the market.

High dose Interleukin-2 (hd Il-2) versus low dose Il-2 plus Interferon in metastatic renal/kidney cancer Optimisation of immunotherapy for metastatic renal cancer is a 'work in progress' subject. At this year's American Society of Clinical Oncology meeting, data from Boston were presented suggesting a...
Nephrectomy followed by Interferon versus Interferon alone as therapy of metastatic kidney cancer It has been established that immunotherapy (interferon or interferon plus other) is the best systemic therapy for kidney/renal cancer that has metastasised. In the past there had been recorded...
Sunitinib therapy in kidney cancer A recent study presented at the American Society for Clinical Oncology annual meeting, compared therapy with sunitinib (an inhibitor of the effector pathway of the VHL oncogene)with interferon...